Posters will be available on the site after July 13.

Name Speakers
201 Impact of COVID-19 on OUD Management and MOUD AccessWilliam Mullen MPH, PA-C, Assoc. Director for Real World Evidence, Indivior
202 Risk of Treatment Failure with Paliperidone Palmitate V Oral Antipsychotics in a Sample of Adults with SchizophreniaH. Lynn Starr MD, Director, Clinical Development, Medical Affairs, Janssen Therapeutics, Inc.
203 Dual Nature of Alchemy: Treatment and Child Visitation Effects on Mental HealthEileen Ahlin PhD, Associate Professor, The Lloyd Society
204 Psychopharmacology Update for Correctional SettingsJustin White CNP, DNP, LCSW, PMHNP, Associate Professor, New Mexico State University
Ernestine Mahar , Lab Manager, Emory University